Pierre Legault - 12 Jan 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, as Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
12 Jan 2023
Transactions value $
-$615,802
Form type
4
Filing time
13 Jan 2023, 15:44:07 UTC
Previous filing
05 Jan 2023
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $227,280 +24,000 +75% $9.47 56,000 12 Jan 2023 Direct
transaction SNDX Common Stock Sale -$641,781 -24,000 -42.86% $26.74 32,000 12 Jan 2023 Direct F1, F2
transaction SNDX Common Stock Options Exercise $135,800 +10,000 +31.25% $13.58 42,000 13 Jan 2023 Direct
transaction SNDX Common Stock Sale -$270,000 -10,000 -23.81% $27 32,000 13 Jan 2023 Direct F1
transaction SNDX Common Stock Options Exercise $67,900 +5,000 +15.62% $13.58 37,000 13 Jan 2023 Direct
transaction SNDX Common Stock Sale -$135,000 -5,000 -13.51% $27 32,000 13 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24,000 -100% $0* 0 12 Jan 2023 Common Stock 24,000 $9.47 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -10,000 -100% $0* 0 13 Jan 2023 Common Stock 10,000 $13.58 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -5,000 -100% $0* 0 13 Jan 2023 Common Stock 5,000 $13.58 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $26.50 to $26.93.
F3 This option is fully vested.